Cite
The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer.
MLA
Cao, Jingjia, et al. “The Genetic Duet of BRAF V600E and TERT Promoter Mutations Predicts the Poor Curative Effect of Radioiodine Therapy in Papillary Thyroid Cancer.” European Journal of Nuclear Medicine & Molecular Imaging, vol. 49, no. 10, Aug. 2022, pp. 3470–81. EBSCOhost, https://doi.org/10.1007/s00259-022-05820-x.
APA
Cao, J., Zhu, X., Sun, Y., Li, X., Yun, C., & Zhang, W. (2022). The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. European Journal of Nuclear Medicine & Molecular Imaging, 49(10), 3470–3481. https://doi.org/10.1007/s00259-022-05820-x
Chicago
Cao, Jingjia, Xiaolu Zhu, Yaru Sun, Xiao Li, Canhua Yun, and Wei Zhang. 2022. “The Genetic Duet of BRAF V600E and TERT Promoter Mutations Predicts the Poor Curative Effect of Radioiodine Therapy in Papillary Thyroid Cancer.” European Journal of Nuclear Medicine & Molecular Imaging 49 (10): 3470–81. doi:10.1007/s00259-022-05820-x.